SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

iBio, Inc. (IBIO) (CIK 0001420720)
Date: March 4, 2026 · CIK: 0001420720 · Accession: 0000000000-26-002235

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293864

Date
March 4, 2026
Author
Division of
Form
UPLOAD
Company
iBio, Inc. (IBIO) (CIK 0001420720)

Letter

Re: iBio, Inc. Registration Statement on Form S-3 Filed February 27, 2026 File No. 333-293864 Dear Martin Brenner:

March 4, 2026

Martin Brenner Chief Executive Officer iBio, Inc. 11750 Sorrento Valley Road, Suite 200 San Diego, CA 92121

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Melissa Palat Murawsky, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 4, 2026

Martin Brenner
Chief Executive Officer
iBio, Inc.
11750 Sorrento Valley Road, Suite 200
San Diego, CA 92121

 Re: iBio, Inc.
 Registration Statement on Form S-3
 Filed February 27, 2026
 File No. 333-293864
Dear Martin Brenner:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tyler Howes at 202-551-3370 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Melissa Palat Murawsky, Esq.
</TEXT>
</DOCUMENT>